Sagittarius Life Science

Sagittarius Life Science FCF Margin

The Free Cash Flow Margin of Sagittarius Life Science (3205.TWO) as of Oct 31, 2026 is -10.53 %. In the previous year, Free Cash Flow Margin was -10.32 % — a change of 2.04% (lower).

FCF Margin

-10.53 %

YoY

2.04%

Last updated:

Free Cash Flow Margin of Sagittarius Life Science is 2025 -10.53 % . Free Cash Flow Margin of Sagittarius Life Science was 2024 -10.32 % . It decreases by 2.04% lower compared to the previous year.

The Sagittarius Life Science FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-14.09 TWD
Jan 1, 2019
-27.17 TWD
Jan 1, 2020
-13.16 TWD
Jan 1, 2021
-6.40 TWD
Jan 1, 2022
-10.20 TWD
Jan 1, 2023
-16.21 TWD
Jan 1, 2024
-10.32 TWD
Jan 1, 2025
-10.53 TWD
The Sagittarius Life Science FCF Margin history
YEARFCF MarginYoY
-10.53 %+2.04%
-10.32 %-36.31%
-16.21 %+58.83%
-10.20 %+59.42%
-6.40 %-51.35%
-13.16 %-51.57%
-27.17 %+92.83%
-14.09 %+148.70%
-5.66 %-123.02%
24.60 %+29.83%
18.95 %+52.51%
12.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sagittarius Life Science Stock analysis

What does Sagittarius Life Science do? Sagittarius Life Science Corp. generates revenue through the manufacture and sale of Chinese and western medicine, including nutrition and health formulations, natural and organic food, beverages, probiotic fermentation products, beauty care ingredients, Chinese herbal medicines, plant new medicines, and health supplies. The company serves domestic markets in Taiwan and overseas markets in Asia and the Americas, distributing its products through established channels. Technical services for pharmaceutical R&D are also a key revenue stream, supporting clients in developing both traditional and modern medicine solutions. The firm's product portfolio targets health-conscious consumers seeking natural and organic solutions, as well as businesses in the pharmaceutical and beauty care industries requiring specialized ingredients and formulations. Domestic sales focus on Taiwan, while international distribution extends to Asian regions outside of Taiwan and the Americas, reflecting a strategic market expansion. Revenue is derived from direct product sales and technical service contracts, with no mention of third-party partnerships or additional revenue streams beyond the described offerings. Sagittarius Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sagittarius Life Science stock

Free Cash Flow Margin of Sagittarius Life Science is -10.53 % in 2025.

Free Cash Flow Margin of Sagittarius Life Science changed from -10.32 % to -10.53 %, representing a 2.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Sagittarius Life Science since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Sagittarius Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sagittarius Life Science

All Key Metrics — Sagittarius Life Science